Skip to main content
Top
Published in: Journal of Nuclear Cardiology 1/2016

01-02-2016 | Editorial

Immortality time and serial myocardial perfusion imaging: Only those who do not die may repeat the exam

Authors: Mario Petretta, MD, Marco Salvatore, MD, Alberto Cuocolo, MD

Published in: Journal of Nuclear Cardiology | Issue 1/2016

Login to get access

Excerpt

Assessment of risk of future events in patients with suspected or known coronary artery disease (CAD) is challenging. Many studies are published every month on prognostic factors, and novel prognostic models and flow-chart are proposed for clinical use. A quantity of data accumulated since the 70’ demonstrates the strength of stress single-photon emission-computed tomography myocardial perfusion imaging (MPI) in predicting outcome.1,2 MPI is also commonly used as a gatekeeper to select patients for coronary revascularization.3,4 The degree of left ventricular (LV) dysfunction and the extent and magnitude of inducible myocardial ischemia are important prognostic variables that can be assessed by MPI. Transient ischemic LV cavity dilation is another high-risk variable associated with the presence of severe angiographic CAD5 and with an adverse outcome.6,7 Serial MPI imaging has been used to compare the effectiveness of intercurrent treatments, within the framework of randomized controlled trials.8-10 Moreover, an analysis of the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study not including patients with intervening cardiac events or revascularization found unexpected resolution of ischemia in most of these patients, potentially because of more aggressive medical treatment of cardiovascular risk factors.11
Literature
1.
2.
go back to reference Shaw LJ, Hage FG, Berman DS, Hachamovitch R, Iskandrian A. Prognosis in the era of comparative effectiveness research: Where is nuclear cardiology now and where should it be? J Nucl Cardiol 2012;19:1026-43.CrossRefPubMed Shaw LJ, Hage FG, Berman DS, Hachamovitch R, Iskandrian A. Prognosis in the era of comparative effectiveness research: Where is nuclear cardiology now and where should it be? J Nucl Cardiol 2012;19:1026-43.CrossRefPubMed
3.
go back to reference Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011;32:1012-24.CrossRefPubMed Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011;32:1012-24.CrossRefPubMed
4.
go back to reference Phillips LM, Hachamovitch R, Berman DS, Iskandrian AE, Min JK, Picard MH, et al. Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIA. J Nucl Cardiol 2013;20:969-75.PubMedCentralCrossRefPubMed Phillips LM, Hachamovitch R, Berman DS, Iskandrian AE, Min JK, Picard MH, et al. Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIA. J Nucl Cardiol 2013;20:969-75.PubMedCentralCrossRefPubMed
5.
go back to reference Petretta M, Acampa W, Daniele S, Petretta MP, Nappi C, Assante R, et al. Transient ischemic dilation in SPECT myocardial perfusion imaging for prediction of severe coronary artery disease in diabetic patients. J Nucl Cardiol 2013;20:45-52.CrossRefPubMed Petretta M, Acampa W, Daniele S, Petretta MP, Nappi C, Assante R, et al. Transient ischemic dilation in SPECT myocardial perfusion imaging for prediction of severe coronary artery disease in diabetic patients. J Nucl Cardiol 2013;20:45-52.CrossRefPubMed
6.
go back to reference Abidov A, Germano G, Hachamovitch R, Berman DS. Gated SPECT in assessment of regional and global left ventricular function: Major tool of modern nuclear imaging. J Nucl Cardiol 2006;13:261-79.CrossRefPubMed Abidov A, Germano G, Hachamovitch R, Berman DS. Gated SPECT in assessment of regional and global left ventricular function: Major tool of modern nuclear imaging. J Nucl Cardiol 2006;13:261-79.CrossRefPubMed
7.
go back to reference Petretta M, Acampa W, Daniele S, Petretta MP, Plaitano M, Cuocolo A. Transient ischemic dilation in patients with diabetes mellitus: prognostic value and effect on clinical outcome after coronary revascularization. Circ Cardiovasc Imaging 2013;6:908-15.CrossRefPubMed Petretta M, Acampa W, Daniele S, Petretta MP, Plaitano M, Cuocolo A. Transient ischemic dilation in patients with diabetes mellitus: prognostic value and effect on clinical outcome after coronary revascularization. Circ Cardiovasc Imaging 2013;6:908-15.CrossRefPubMed
8.
go back to reference Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, COURAGE Investigators, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91.CrossRefPubMed Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, COURAGE Investigators, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91.CrossRefPubMed
9.
go back to reference Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol 2012;19:658-69.PubMedCentralCrossRefPubMed Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol 2012;19:658-69.PubMedCentralCrossRefPubMed
10.
go back to reference Mahmarian JJ, Dakik HA, Filipchuk NG, Shaw LJ, Iskander SS, Ruddy TD, INSPIRE Investigators, et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol 2006;48:2458-67.CrossRefPubMed Mahmarian JJ, Dakik HA, Filipchuk NG, Shaw LJ, Iskander SS, Ruddy TD, INSPIRE Investigators, et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol 2006;48:2458-67.CrossRefPubMed
11.
go back to reference Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators, et al. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care 2007;30:2892-8.CrossRefPubMed Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators, et al. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care 2007;30:2892-8.CrossRefPubMed
12.
go back to reference Ghimire G, Hage FG, Heo J, Iskandrian AE. Regadenoson: A focused update. J Nucl Cardiol 2013;20:284-8.CrossRefPubMed Ghimire G, Hage FG, Heo J, Iskandrian AE. Regadenoson: A focused update. J Nucl Cardiol 2013;20:284-8.CrossRefPubMed
13.
go back to reference Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, Iskandrian AE, Bateman TM, et al. Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: A quantitative analysis from the ADVANCE MPI trials. J Nucl Cardiol 2015;22:248-61.CrossRefPubMed Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, Iskandrian AE, Bateman TM, et al. Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: A quantitative analysis from the ADVANCE MPI trials. J Nucl Cardiol 2015;22:248-61.CrossRefPubMed
14.
go back to reference Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J, et al. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. JACC Cardiovasc Imaging 2012;5:1014-21.CrossRefPubMed Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J, et al. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. JACC Cardiovasc Imaging 2012;5:1014-21.CrossRefPubMed
15.
go back to reference Hage FG, Ghimire G, Lester D, Mckay J, Bleich S, El-Hajj S, Iskandrian AE. The prognostic value of regadenoson myocardial perfusion imaging. J Nucl Cardiol 2015. doi:10.1007/s12350-014-0050-y. Hage FG, Ghimire G, Lester D, Mckay J, Bleich S, El-Hajj S, Iskandrian AE. The prognostic value of regadenoson myocardial perfusion imaging. J Nucl Cardiol 2015. doi:10.​1007/​s12350-014-0050-y.
16.
go back to reference Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI17-23.PubMed Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI17-23.PubMed
17.
go back to reference Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol 2003;92:827-9.CrossRefPubMed Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol 2003;92:827-9.CrossRefPubMed
18.
go back to reference Kuznetsova T, Thijs L, Knez J, Cauwenberghs N, Petit T, Gu YM, et al. Longitudinal changes in left ventricular diastolic function in a general population. Circ Cardiovasc Imaging 2015;8:e002882.CrossRefPubMed Kuznetsova T, Thijs L, Knez J, Cauwenberghs N, Petit T, Gu YM, et al. Longitudinal changes in left ventricular diastolic function in a general population. Circ Cardiovasc Imaging 2015;8:e002882.CrossRefPubMed
19.
go back to reference Iskandrian AE, Hage FG, Shaw LJ, Mahmarian JJ, Berman DS. Serial myocardial perfusion imaging: Defining a significant change and targeting management decisions. JACC Cardiovasc Imaging 2014;7:79-96.CrossRefPubMed Iskandrian AE, Hage FG, Shaw LJ, Mahmarian JJ, Berman DS. Serial myocardial perfusion imaging: Defining a significant change and targeting management decisions. JACC Cardiovasc Imaging 2014;7:79-96.CrossRefPubMed
20.
go back to reference El Hajj S, AlJaroudi WA, Farag A, Bleich S, Manaoragada P, Iskandrian AE, et al. Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients. J Nucl Cardiol 2015. doi:10.1007/s12350-015-0174-8. El Hajj S, AlJaroudi WA, Farag A, Bleich S, Manaoragada P, Iskandrian AE, et al. Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients. J Nucl Cardiol 2015. doi:10.​1007/​s12350-015-0174-8.
21.
go back to reference Acampa W, Cantoni V, Green R, Maio F, Daniele S, Nappi C, et al. Prognostic value of normal stress myocardial perfusion imaging in diabetic patients: A meta-analysis. J Nucl Cardiol 2014;21:893-902.CrossRefPubMed Acampa W, Cantoni V, Green R, Maio F, Daniele S, Nappi C, et al. Prognostic value of normal stress myocardial perfusion imaging in diabetic patients: A meta-analysis. J Nucl Cardiol 2014;21:893-902.CrossRefPubMed
22.
go back to reference Wolbers M, Koller MT, Stel VS, Schaer B, Jager KJ, Leffondré K, et al. Competing risks analyses: Objectives and approaches. Eur Heart J 2014;35:2936-41.PubMedCentralCrossRefPubMed Wolbers M, Koller MT, Stel VS, Schaer B, Jager KJ, Leffondré K, et al. Competing risks analyses: Objectives and approaches. Eur Heart J 2014;35:2936-41.PubMedCentralCrossRefPubMed
23.
go back to reference Acampa W, Petretta M, Cuocolo R, Daniele S, Cantoni V, Cuocolo A. Warranty period of normal stress myocardial perfusion imaging in diabetic patients: A propensity score analysis. J Nucl Cardiol 2014;21:50-6.CrossRefPubMed Acampa W, Petretta M, Cuocolo R, Daniele S, Cantoni V, Cuocolo A. Warranty period of normal stress myocardial perfusion imaging in diabetic patients: A propensity score analysis. J Nucl Cardiol 2014;21:50-6.CrossRefPubMed
24.
go back to reference Fitzmaurice GM, Ravichandran C. A primer in longitudinal data analysis. Circulation 2008;118:2005-10.CrossRefPubMed Fitzmaurice GM, Ravichandran C. A primer in longitudinal data analysis. Circulation 2008;118:2005-10.CrossRefPubMed
25.
go back to reference Shariff SZ, Cuerden MS, Jain AK, Garg AX. The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 2008;19:841-3.CrossRefPubMed Shariff SZ, Cuerden MS, Jain AK, Garg AX. The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 2008;19:841-3.CrossRefPubMed
26.
go back to reference Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, St Peter WL. Issues regarding ‘immortal time’ in the analysis of the treatment effects in observational studies. Kidney Int 2012;81:341-50.CrossRefPubMed Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, St Peter WL. Issues regarding ‘immortal time’ in the analysis of the treatment effects in observational studies. Kidney Int 2012;81:341-50.CrossRefPubMed
27.
go back to reference Webster NR. Professors live longer than doctors: Immortality bias in survival analysis. Br J Anaesth 2011;106:161-3.CrossRefPubMed Webster NR. Professors live longer than doctors: Immortality bias in survival analysis. Br J Anaesth 2011;106:161-3.CrossRefPubMed
28.
go back to reference Crowther MJ, Abrams KR, Lambert PC. Flexible parametric joint modelling of longitudinal and survival data. Stat Med 2012;31:4456-71.CrossRefPubMed Crowther MJ, Abrams KR, Lambert PC. Flexible parametric joint modelling of longitudinal and survival data. Stat Med 2012;31:4456-71.CrossRefPubMed
29.
go back to reference Farzaneh-Far A, Phillips HR, Shaw LK, Starr AZ, Fiuzat M, O’Connor CM, et al. Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction. JACC Cardiovasc Imaging 2012;5:715-24.CrossRefPubMed Farzaneh-Far A, Phillips HR, Shaw LK, Starr AZ, Fiuzat M, O’Connor CM, et al. Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction. JACC Cardiovasc Imaging 2012;5:715-24.CrossRefPubMed
Metadata
Title
Immortality time and serial myocardial perfusion imaging: Only those who do not die may repeat the exam
Authors
Mario Petretta, MD
Marco Salvatore, MD
Alberto Cuocolo, MD
Publication date
01-02-2016
Publisher
Springer US
Published in
Journal of Nuclear Cardiology / Issue 1/2016
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-015-0171-y

Other articles of this Issue 1/2016

Journal of Nuclear Cardiology 1/2016 Go to the issue

Journal of Nuclear Cardiology News Update

Leading ASNC in 2016: Putting the Strategic Plan into Action